Next-generation connected devices to support personalized care in growth hormone disorders in the Gulf Cooperation Council region

This is the authors' abstract. We don't add key points for this paper.

Aims To assess the potential acceptance of digital health devices for administering pediatric growth hormone (GH) therapy and to understand how clinicians in Gulf Cooperation Council (GCC) countries perceive the evolution of health technologies. The only electronic device presently available for GH therapy in GCC countries is easypod ® . Participants and Methods Expert panel discussions were conducted in Jeddah, Saudi Arabia in February 2023, involving 10 pediatric endocrinologists experienced in the treatment of children with growth failure. Participants provided perceptions and opinions on the current easypod device, EP2, and the next-generation device, EP3. Predefined discussion topics were related to usefulness, ease-of-use, and recommendations for the EP2 and EP3 devices. Thematic analysis of opinions was assessed. Results Digital devices are perceived as very useful to support remote monitoring of patient adherence and improve clinical decisions. Participants rated the larger touch-screen and the automatic data transmission via mobile networks as the most important innovations in EP3, making it easier to use and learn. Providing accurate, objective data on adherence enables the integration of real-time monitoring into current clinical practice and improves clinical decision-making and analysis. Participants indicated that they would recommend the use of EP3 to their patients and families. Conclusions The new functionalities in the EP3 device represent a positive technological progression recognized and supported by clinicians and patients. The larger touch-screen, rechargeable battery, and automatic data transmission are considered the most important advances. Integrating EP3 into clinical practice enhances decision-making and personalization of care for children receiving GH therapy.